COVID-19 Resources Hub

We are highlighting open access, peer-reviewed content with relevance to resource-variable settings. Please check back as we are making new content and adding new resources soon.  Please send suggestions and check out our full Resource Library.

All COVID Resources

View full resources page

Results:

Recently added

Information for clinicians on mechanism of action for Molnupiravir, contraindications & indications, general dosage guidelines

L1
L2
L3
By RISE
English

Information for clinicians on mechanism of action for Paxlovid, contraindications & indications, general dosage guidelines.

L1
L2
L3
By RISE
English

Brief overview of the Test-to-Treat activity, answers key questions on purpose and target population

L1
L2
L3
By RISE
English

Information on purpose and use of self-tests in various environments.

L1
L2
L3
By RISE
English

Check out our OCC Job Aid Builder Tool for more free content to make your own job aid. Topics include respiratory care, emergency algorithms, critical care medications, procedures with more topics and more languages coming soon.

L1
L2
L3

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

L1
L2
L3
By WHO / OMS
English

Fiche d'information de deux pages conçue pour les patients qui prennent du molnupiravir. Il est destiné à être imprimé recto-verso et plié en deux.

L1
L2
L3
By EpiC
Français

Hoja de información de dos páginas diseñada para pacientes que están tomando molnupiravir. Está destinado a ser impreso a doble cara y doblado por la mitad.

L1
L2
L3
By EpiC
Español

Two-page information sheet designed for patients who are taking molnupiravir. It is intended to be printed double-sided and folded in half.

L1
L2
L3
By EpiC
English

Two-page information sheet designed for patients who are taking Paxlovid. It is intended to be printed double-sided and folded in half

L1
L2
L3
By EpiC
English

This slide deck covers topics such as triage, testing and clinical management of COVID-19, including treatment with oral antiviral therapy.
This facilitator guide accompanies the slide deck and includes a script for the facilitator to teach this topic.

L1
L2
L3
By EpiC
English

This document provides answers to frequently asked questions about the COVID-19 Test to Treat strategy for clinicians, prescribers and health care teams.

L1
L2
L3
By EpiC
English

This calculator allows users to estimate the number of courses of oral antivirals that might be required during a calendar period, based on infection rate inputs.

T2T Quantification Tool
L2
L3
By STAR-UCSF
English

Guidelines on COVID-19 Test to Treat, by the Africa Centres for Disease Control and Prevention (Guidance to Africa Union Member States)

L1
L2
L3
By Africa CDC
English

Cet algorithme et ce guide de mise en œuvre sont destinés à aider les cliniciens au point de service à initier un traitement antiviral oral pour la COVID-19. Sur la base des données, le nirmatrelvir/ritonavir (NMV/r) est l'agent préféré, suivi du molnupiravir.

Ces ressources ont été créées par les partenaires EpIC, RISE, STAR-UCSF.

L1
L2
L3
By OpenCriticalCare.org
Français
English

Este algoritmo es para ayudar a los médicos en el punto de atención a iniciar el tratamiento con antivíricos por vía oral para el COVID-19. En función de los datos, nirmatrelvir/ritonavir (NMV/r) se prefiere, seguido de molnupiravir.

Estos recursos fueron creados por los colaboradores EpIC, RISE, STAR-UCSF.

L1
L2
L3
By OpenCriticalCare.org
English
Español
L1
L2
L3
By STAR-UCSF
1h 1min
English

This algorithm and implementation guide are intended to help clinicians at the point of care initiate oral antiviral treatment for COVID-19. Based on efficacy data, nirmatrelvir/ritonavir (NMV/r) is the preferred agent, followed by molnupiravir.

These tools were created by USAID Implementing partners EpIC, RISE, STAR-UCSF.

L1
L2
L3

Menu

Feedback

Not 
at all

Very 


Your message was sent successfully.